Cogent Biosciences
COGT· Manufacturing· Fiscal year ends in December
Andrew Robbins is the CEO of Cogent Biosciences and was paid $27.8M in FY2025 (Dec), up 465%.
Executives5
See all- 1Andrew RobbinsChief Executive OfficerFY2025
- 2Jessica SachsChief Medical OfficerFY2025
- 3John RobinsonChief Scientific OfficerFY2025
- 4Cole PinnowChief Commercial OfficerFY2025
- 5John GreenChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCogent Biosciences paid its 5 named executives $63.5M in total in FY2025 (Dec). CEO Andrew Robbins was paid $27.8M of that.
| Name | |||
|---|---|---|---|
| Andrew RobbinsChief Executive Officer | |||
| Jessica SachsChief Medical Officer | |||
| John RobinsonChief Scientific Officer | |||
| Cole PinnowChief Commercial Officer | Not disclosed | ||
| John GreenChief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe FY2025 (Dec) proxy of Cogent Biosciences names 20 peer companies for pay. Among Cogent Biosciences and these peers, CEO pay was the highest of 7 and total shareholder return was the highest of 7.
1st highest of 7in Cogent Biosciences and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 7in Cogent Biosciences and its pay peers, FY2025 (Dec) by total shareholder return:
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Arlene M. MorrisDirector · 6 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Matthew E. RosDirector · 6 yr on the boardIndependentAudit, Nominating—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Feb 17, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Feb 26, 2024 | FY2023 |
